The role of general nuclear medicine in breast cancer

Greene, Lacey; Wilkinson, Deborah

doi:10.1002/jmrs.97

Cited by 27 publications

(17 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotracer-based imaging approaches, such as single-photon emission computed tomography (SPECT) might provide a non-invasive in vivo assessment providing information about tumor localization and progression [23,26]. The use of radionuclides combined with molecules or existing pharmaceutical compounds, such as antitumor drugs, which preferentially accumulate in tumor tissue, has significant importance since they might enable an early and more accurate diagnosis [1–3]. …”

Section: Discussionmentioning

confidence: 99%

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Monteiro

Fernandes

Castro

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The high incidence and mortality of breast cancer supports efforts to develop innovative imaging probes to effectively diagnose, evaluate the extent of the tumor, and predict the efficacy of tumor treatments while concurrently and selectively delivering anticancer agents to the cancer tissue. In the present study we described the preparation of technetium–99 m (99mTc)-labeled paclitaxel (PTX) and evaluated its feasibility as a radiotracer for breast tumors (4T1) in BALB/c mice. Thin Layer Chromatography (TLC) was used to determine the radiochemical purity and in vitro stability of 99mTc-PTX. PTX micelles showed a unimodal distribution with mean diameter of 13.46 ± 0.06 nm. High radiochemical purity (95.8 ± 0.3%) and in vitro stability (over than 95%), up to 24 h, were observed. Blood circulation time of 99mTc-PTX was determined in healthy BALB/c mice. 99mTc-PTX decays in a one-phase manner with a half-life of 464.3 minutes. Scintigraphic images and biodistribution were evaluated at 4, 8 and 24 h after administration of 99mTc-PTX in 4T1 tumor-bearing mice. The data showed a significant uptake in the liver, spleen and kidneys, due to the importance of these routes for excretion. Moreover, high tumor uptake was achieved, indicated by high tumor-to-muscle ratios. These findings indicate the usefulness of 99mTc-PTX as a radiotracer to identify 4T1 tumor in animal models. In addition, 99mTc-PTX might be used to follow-up treatment protocols in research, being able to provide information about tumor progression after therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Monteiro

Fernandes

Castro

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Therefore, the MIBI radiopharmaceutical is widely used for the diagnosis of myocardial perfusion in order to evaluate ischemic heart diseases and locate abnormal myocardium [9]. Several studies also developed this radiopharmaceutical to diagnose parathyroid gland disorders in cases of hyperthyroidism and breast cancer (oncology) [10][11][12]. In addition, the MIBI radiopharmaceutical can also be used for renal oncocytomas, diagnosis of metastatic cancer, detection of recurrent gliomas after radiotherapy, and evaluation of response to chemotherapy [11,13].…”

Section: Radiopharmaceuticalsmentioning

confidence: 99%

Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging

et al. 2016

View full text Add to dashboard Cite

Tc-MIBI Stability of liquid phase kit Myocardial imagingThe 99m Tc-MIBI radiopharmaceutical has been used in nuclear medicine in Indonesia for myocardial imaging. BATAN researchers have mastered the technology to manufacture MIBI as a liophylized kit. A reformulation of MIBI radiopharmaceutical has been conducted to improve the stability of the kit especially in the liquid-phase kit. Basically, radiopharmaceuticals in liquid form are not different from the dry kit. However in the manufacturing of liquid-phase kit, lyophilization process was not done. To improve the stability of liquid kit, a reformulation of the components was conducted by using two separate vials (Formulation 2) and the characteristics were compared with the one-vial formulation (Formulation 1). The MIBI Formulation 2 consists of two vials, vial A containing 0.06 mg of SnCl 2 2H 2 O and 2.6 mg Sodium Citrate 2H 2 O and vial B containing 0.5 mg of [Cu(MIBI) 4 ]BF 4 , 1 mg of cysteine hydrochloride, and 20 mg of mannitol. The purposes of this study were to determine the stability of two different formulations of MIBI as a liquid-phase kit, to compare their stability in different storage condition such as in refrigerator and freezer, and to compare the ratio of activities attained between target and nontarget organs after injection to animal model. As a diagnostic agent, MIBI was reconstituted with Technetium-99m as radionuclide tracer to 99m Tc-MIBI labeled compound. The radiochemical purity of 99m Tc-MIBI was determined by chromatography method using alumina thin-layer chromatography paper as the stationary phase and ethanol 95% as the mobile phase. The results showed MIBI Formulation 2 has a higher stability than Formulation 1. Formulation 2 also maintained a 96.68% radiochemical purity under 52-day storage and attained a target-to-nontarget activity ratio of 8.22.

show abstract

“…[ 1 ] Approximately 0.68%–1.7% of myocardial perfusion scintigrams have noncardiac findings of varying importance, including tumors. [ 2 3 ] Low-dose computed tomography (CT), acquired routinely for attenuation correction,[ 4 ] facilitates anatomic correlation.…”

Section: Introductionmentioning

confidence: 99%

Breast uptake on a myocardial perfusion scan

Morales

Apostol

2021

World J Nucl Med

View full text Add to dashboard Cite

A 42-year-old female underwent a myocardial perfusion scan (MPS) for the evaluation of coronary artery disease. Raw and cine loop images hinted at abnormal tracer accumulation in the chest. Review of short-axis slices and low-dose computed tomography images taken for attenuation correction and their subsequent fusion confirmed the presence of focal tracer uptake localized to nodular breast masses. This case demonstrates that despite MPS not being optimized to detect breast pathologies, careful inspection of unprocessed images and the application of available software for fusion can help detect concurrent pathology.

show abstract

The role of general nuclear medicine in breast cancer

Cited by 27 publications

References 82 publications

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo

Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging

Breast uptake on a myocardial perfusion scan

Contact Info

Product

Resources

About